Defunct Company
Total Trials
12
As Lead Sponsor
10
As Collaborator
2
Total Enrollment
1,588
NCT00095108
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: May 31, 2004
Completion: Jan 31, 2007
NCT00245336
Study of Recombinant Human Thrombin for Bleeding During Surgery
Phase: Phase 3
Start: Oct 31, 2005
Completion: Jul 31, 2006
NCT00347971
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
Start: Jun 30, 2006
Completion: Apr 30, 2008
NCT00371215
Study of Recombinant Human Thrombin for Bleeding During Autologous Skin Grafting
Phase: Phase 2
Start: Aug 31, 2006
Completion: Jun 30, 2007
NCT00389285
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
Phase: Phase 1/2
Start: Oct 31, 2006
Completion: May 31, 2009
NCT00491608
Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis
Start: Jun 30, 2007
Completion: Jul 31, 2008
NCT00514085
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Role: Collaborator
Start: Dec 13, 2007
Completion: Jul 4, 2012
NCT00565539
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
Start: Dec 31, 2007
Completion: Oct 31, 2009
NCT00573157
The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
Phase: Phase 2/3
Completion: Apr 30, 2009
NCT00813904
Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis
Phase: Phase 4
Start: Jan 31, 2009
Completion: Jul 31, 2010
NCT00859547
Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants
Start: Mar 31, 2009
Completion: Jan 31, 2010
NCT01001754
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Start: May 31, 2010
Completion: May 31, 2012